ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,800Medicare Part D Prescriptions Filled, Including Refills

Rank: 36 out of 298

$377K Total Retail Price of All Prescriptions

Rank: 65 out of 298

365 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
49% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in South Dakota
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 365 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

15% of this provider’s 365 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

2% of this provider’s 9,297 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

16% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$38 was the average price of a prescription from this provider, compared to $50 among peers.

Prescriptions per Patient

27 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in South Dakota
FUROSEMIDE 458 431 1 5
AMLODIPINE BESYLATE 400 392 2 6
SIMVASTATIN 330 315 3 2
POTASSIUM CHLORIDE 315 305 4 11
LISINOPRIL 307 289 5 4
HYDROCODONE-ACETAMINOPHEN 301 256 S3 6 8
LEVOTHYROXINE SODIUM 300 290 7 1
OMEPRAZOLE 293 275 8 3
POLYETHYLENE GLYCOL 3350 271 264 9 29
ATENOLOL 257 250 10 16
HYDROCHLOROTHIAZIDE 256 244 11 13
WARFARIN SODIUM 251 235 12 7
SERTRALINE HCL 178 178 13 19
DONEPEZIL HCL 175 175 14 22
METFORMIN HCL 149 140 15 10
CITALOPRAM HBR 142 141 16 17
GABAPENTIN 133 114 17 20
ISOSORBIDE MONONITRATE ER 124 124 18 45
LOSARTAN POTASSIUM 113 108 19 18
METOPROLOL TARTRATE 113 107 19 9
GEMFIBROZIL 113 113 19 65
METOPROLOL SUCCINATE 110 101 22 12
DIGOXIN 103 101 23 27
CLOPIDOGREL 103 94 23 36
RANITIDINE HCL 102 92 25 59
MIRTAZAPINE 99 99 26 37
CARBIDOPA-LEVODOPA 91 91 27 49
FENTANYL 88 88 S2 28 32
ATORVASTATIN CALCIUM 78 77 29 14
OXYBUTYNIN CHLORIDE ER 77 77 30 121
NAMENDA 72 72 31 35
FELODIPINE ER 68 68 32 124
DIOVAN 67 67 33 47
ZOLPIDEM TARTRATE 66 64 34 25
GLIPIZIDE ER 63 62 35 95
CIPROFLOXACIN HCL 63 57 35 56
TRAMADOL HCL 61 56 37 15
NITROGLYCERIN PATCH 61 61 37 106
SPIRONOLACTONE 59 59 39 34
CARVEDILOL 59 59 39 23
ENALAPRIL MALEATE 58 58 41 58
AMITRIPTYLINE HCL 56 56 R 42 51
TRIAMTERENE-HCTZ 56 55 42 43
ALENDRONATE SODIUM 55 55 44 21
ZETIA 50 50 45 83
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 8, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.